TMPRSS2-ERG rearrangement, the most common ETS gene fusion in prostate cancer, brings ERG expression under androgen control via androgen receptor-mediated TMPRSS2 regulation and results in over-expression of ERG protein [3]. Here, AR is linked to prostate cancer.